Qualigen Therapeutics, Inc. Promotes Shishir Sinha to Chief Operating Officer Position
March 09 2021 - 8:30AM
Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a biotechnology company
focused on developing novel therapeutics for the treatment of
cancer and infectious diseases, announced today that it has
promoted long-time officer Shishir Sinha to the newly created
position of Chief Operating Officer. Mr. Sinha is based in
Qualigen’s corporate headquarters in Carlsbad, California.
“Shishir Sinha has been valuable to Qualigen
Therapeutics for 15 years. He is woven into the fabric of the
Company and we are very grateful for his substantial contributions
over many years,” said Michael Poirier, President, Chief Executive
Officer and Chairman of Qualigen. “We are confident that Shishir’s
leadership in operations and quality groups in the medical
diagnostics industry coupled with his current therapeutics
experience is exactly what is needed to deliver our strategy.”
“We look forward to leverage Shishir’s expertise
into this expanded role that includes therapeutics project and
program management to further contribute to our mission to put
patients first while building shareholder value,” said Amy
Broidrick, EVP, Chief Strategy Officer.
About Qualigen Therapeutics, Inc.
Qualigen Therapeutics, Inc. is a biotechnology
company focused on developing novel therapeutics for the treatment
of cancer and infectious diseases, as well as maintaining and
expanding its core FDA-approved FastPack® System, which has been
used successfully in diagnostics for 20 years. The Company's cancer
therapeutics pipeline includes ALAN (AS1411-GNP), RAS-F and STARS™.
ALAN (AS1411-GNP) is a DNA coated gold nanoparticle cancer drug
candidate that has the potential to target various types of cancer
with minimal side effects. The foundational nucleolin-targeting DNA
aptamer of ALAN, AS1411, is also a drug candidate for use in
treating COVID-19 and other viral-based infectious diseases. RAS-F
is a family of RAS oncogene protein-protein interaction inhibitor
small molecules for preventing mutated RAS genes’ proteins from
binding to their effector proteins; preventing this binding could
stop tumor growth, especially in pancreatic, colorectal and lung
cancers. STARS is a DNA/RNA-based treatment device candidate for
removal from circulating blood of precisely targeted tumor-produced
and viral compounds.
Because Qualigen's therapeutic candidates are
still in the development stage, Qualigen's only products that are
currently commercially available are FastPack System diagnostic
instruments and test kits, used in physician offices, clinics and
small hospitals around the world. The FastPack System menu includes
rapid point-of-care diagnostic tests for cancer, men's health,
hormone function, vitamin D status and antibodies against
SARS-CoV-2. Qualigen's facility in Carlsbad, California is FDA and
ISO Certified and its FastPack product line is sold worldwide by
its commercial partner Sekisui Diagnostics, LLC.
For more information on Qualigen Therapeutics,
Inc., please visit https://www.qualigeninc.com/.
Forward-Looking Statements
This news release contains forward-looking
statements by the Company that involve risks and uncertainties and
reflect the Company's judgment as of the date of this release.
Actual events or results may differ from the Company’s
expectations. For example, there can be no assurance that any
clinical trials will be approved to begin by or will proceed as
contemplated by any projected timeline; that the Company will
successfully develop any drugs or therapeutic devices; that
preclinical or clinical development of the Company's drugs or
therapeutic devices will be successful; that future clinical trial
data will be favorable or that such trials will confirm any
improvements over other products or lack negative impacts; that any
drugs or therapeutic devices will receive required regulatory
approvals or that they will be commercially successful; that
patents will issue on the Company’s owned and in-licensed patent
applications; that such patents, if any, and the Company’s current
owned and in-licensed patents would prevent competition; that the
Company will be able to procure or earn sufficient working capital
to complete the development, testing and launch of the Company’s
prospective therapeutic products; that the Company will be able to
maintain or expand market demand and/or market share for the
Company’s diagnostic products generally, particularly in view of
COVID-19-related deferral of patients’ physician-office visits and
FastPack reimbursement pricing challenges; that adoption and
placement of FastPack PRO System instruments (which are the only
FastPack instruments on which the Company's SARS-CoV-2 IgG test
kits can be run) will be widespread; that the Company will be able
to manufacture the FastPack PRO System instruments and SARS-CoV-2
IgG test kits successfully; that any commercialization of the
FastPack PRO System instruments and SARS-CoV-2 IgG test kits will
be profitable; or that the FDA will ultimately approve an Emergency
Use Authorization for the Company’s SARS-CoV-2 IgG test. The
Company’s stock price could be harmed if any of the events or
trends contemplated by the forward-looking statements fails to
occur or is delayed or if any actual future event otherwise differs
from expectations. Additional information concerning these and
other risk factors affecting the Company's business (including
events beyond the Company's control, such as epidemics and
resulting changes) can be found in the Company's prior filings with
the Securities and Exchange Commission, available at www.sec.gov.
The Company disclaims any intent or obligation to update these
forward-looking statements beyond the date of this news release,
except as required by law. This caution is made under the safe
harbor provisions of the Private Securities Litigation Reform Act
of 1995.
Investor Relations:
David Kugelman, President and CEOAtlanta Capital Partners,
LLC(404) 856-9157 Office(866) 692-6847 Toll Free - U.S. &
Canadadk@atlcp.com
Tony Schor, PresidentInvestor Awareness, Inc. (847)
971-0922tony@investorawareness.com
- Qualigen Therapeutics, Inc.
Qualigen Therapeutics (NASDAQ:QLGN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Qualigen Therapeutics (NASDAQ:QLGN)
Historical Stock Chart
From Apr 2023 to Apr 2024